ISRCTN80154838已完成未知
A randomised, double-blind, placebo-controlled, four-way crossover, two-part study investigating the pharmacodynamic effect of DSP-2230 using the ID Capsaicin and UVB models in healthy male subjects, using pregabalin and ibuprofen lysine as positive controls.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •All subjects (males) will be in good health aged 18 - 55 years with no evidence of systemic disease and be able to comply with all aspects of the protocol and able to give written informed consent to participate in the study.
排除标准
- •All subjects will not have, or have had a history of, clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, haematological or other major disorders. They will not have, or have had a history of, drug or alcohol abuse and will not have participated in a clinical study with an investigational medicinal product (IMP) within 3 months of randomisation into the current study and will not have donated or lost > 500 mL of blood or blood products in the 3 months preceding the start of dosing.
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on the allergen-induced asthmatic response in subjects with mild asthma.subjects with mild asthmaMedDRA version: 12.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2010-019465-28-SEGlaxoSmithKline Research & Development Ltd24
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, five parallel groups study investigating the efficacy and safety of BI 1356 BS (1mg, 5mg and 10mg administered orally once daily) over 12 weeks as add-on therapy in patients with type 2 diabetes and insufficient glycaemic control despite metformin therapy, including an open-label glimepiride treatment arm.Patients with type 2 diabetesMedDRA version: 8.1 Level: PT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependentEUCTR2005-004597-24-GBBoehringer Ingelheim Limited375
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, five parallel groups study investigating the efficacy and safety of BI 1356 BS (1mg, 5mg and 10mg administered orally once daily) over 12 weeks as add-on therapy in patients with type 2 diabetes and insufficient glycaemic control despite metformin therapy, including an open-label glimepiride treatment arm.Patients with type 2 diabetesMedDRA version: 8.1Level: PTClassification code 10012613EUCTR2005-004597-24-SEBoehringer Ingelheim AB500
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, five parallel groups study investigating the efficacy and safety of BI 1356 BS (1mg, 5mg and 10mg administered orally once daily) over 12 weeks as add-on therapy in patients with type 2 diabetes and insufficient glycaemic control despite metformin therapy, including an open-label glimepiride treatment arm.Patients with type 2 diabetesMedDRA version: 8.1Level: PTClassification code 10012613EUCTR2005-004597-24-SKBoehringer Ingelheim Limited375
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, five parallel groups efficacy and safety exploratory study comparing BI 1356 BS (1mg, 5mg and 10mg) to open label glimepiride each administered orally once daily over 12 weeks as add-on therapy in patients with type 2 diabetes and insufficient glycaemic control despite metformin therapyPatients with type 2 diabetesMedDRA version: 8.1Level: PTClassification code 10012613EUCTR2005-004597-24-DEBoehringer Ingelheim Pharma GmbH & Co. KG375